Skip to main content
Erschienen in: Inflammation Research 1/2017

28.09.2016 | IAIS Lifetime Achievement Award

Progress does not just come in giant leaps: adapting techniques for the study of inflammation to novel applications

verfasst von: Michael J. Parnham

Erschienen in: Inflammation Research | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Discussion of the relevance of suitable experimental models for the effective translation of drug effects to clinical inflammatory diseases has a long history. Much emphasis is placed these days on genetically transformed mice, which may have developmental drawbacks. But are established models redundant?

Findings

Drawn from personal experience, examples are provided of the success of tinkering with technology in the context of inflammation. These include the use of specific dietary deficiency conditions, the development of new applications for established drugs and the introduction of a variety of readouts to assess outcome in studies on established disease models. Such approaches have been used to demonstrate inflammation-modulating effects of prostaglandin E, in the development of ebselen, for the introduction of immunomodulatory macrolide drugs and in new approaches to the therapy of multiple sclerosis.

Conclusion

Fine tuning of experimental approaches and evaluation technologies can often still provide innovative, clinically relevant insights into the potential beneficial effects of drugs and pharmacological agents. 
Literatur
2.
Zurück zum Zitat Ferreira SH, De Souza Costa F. A laminar flow superfusion technique with much increased sensitivity for the detection of smooth muscle-stimulating substances. Eur J Pharmacol. 1976;39:379–81.CrossRefPubMed Ferreira SH, De Souza Costa F. A laminar flow superfusion technique with much increased sensitivity for the detection of smooth muscle-stimulating substances. Eur J Pharmacol. 1976;39:379–81.CrossRefPubMed
3.
Zurück zum Zitat Bult H, Parnham MJ, Bonta IL. Bioassay by cascade superfusion using a highly sensitive laminar flow technique. J Pharm Pharmacol. 1977;29:369–70.CrossRefPubMed Bult H, Parnham MJ, Bonta IL. Bioassay by cascade superfusion using a highly sensitive laminar flow technique. J Pharm Pharmacol. 1977;29:369–70.CrossRefPubMed
4.
Zurück zum Zitat Adolfs MJ, Parnham MJ, Vincent JE, Zijlstra FJ. Detection of small amounts of prostaglandin (PG)-like material and rabbit aorta contracting substance (RCS) released into the blood of the rat [proceedings]. Br J Pharmacol. 1977;60:317P.PubMedPubMedCentral Adolfs MJ, Parnham MJ, Vincent JE, Zijlstra FJ. Detection of small amounts of prostaglandin (PG)-like material and rabbit aorta contracting substance (RCS) released into the blood of the rat [proceedings]. Br J Pharmacol. 1977;60:317P.PubMedPubMedCentral
5.
Zurück zum Zitat Parnham MJ. Determinants of inflammation test selection: in vitro or in vivo? Agents Actions. 1986;17:327–8.CrossRefPubMed Parnham MJ. Determinants of inflammation test selection: in vitro or in vivo? Agents Actions. 1986;17:327–8.CrossRefPubMed
6.
Zurück zum Zitat Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature. 2011;471:602–7.CrossRefPubMedPubMedCentral Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature. 2011;471:602–7.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol. 2002;244:305–18.CrossRefPubMed Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol. 2002;244:305–18.CrossRefPubMed
8.
Zurück zum Zitat Aspinall RL, Cammarat PS. Effect of prostaglandin-E2 on adjuvant arthritis. Nature. 1969;224:1320.CrossRefPubMed Aspinall RL, Cammarat PS. Effect of prostaglandin-E2 on adjuvant arthritis. Nature. 1969;224:1320.CrossRefPubMed
9.
Zurück zum Zitat Zurier RB, Quagliat F. Effect of prostaglandin-E1 on adjuvant arthritis. Nature. 1971;234:304.CrossRefPubMed Zurier RB, Quagliat F. Effect of prostaglandin-E1 on adjuvant arthritis. Nature. 1971;234:304.CrossRefPubMed
10.
Zurück zum Zitat Zurier RB, Ballas M. Prostaglandin E 1 (PGE 1) suppression of adjuvant arthritis histopathology. Arthritis Rheum. 1973;16:251–7.CrossRefPubMed Zurier RB, Ballas M. Prostaglandin E 1 (PGE 1) suppression of adjuvant arthritis histopathology. Arthritis Rheum. 1973;16:251–7.CrossRefPubMed
11.
Zurück zum Zitat Zor U, Kaneko T, Schneider HP, McCann SM, Lowe IP, Bloom G, et al. Stimulation of anterior pituitary adenyl cyclase activity and adenosine 3′:5′-cyclic phosphate by hypothalamic extract and prostaglandin E1. Proc Natl Acad Sci USA. 1969;63:918–25.CrossRefPubMedPubMedCentral Zor U, Kaneko T, Schneider HP, McCann SM, Lowe IP, Bloom G, et al. Stimulation of anterior pituitary adenyl cyclase activity and adenosine 3′:5′-cyclic phosphate by hypothalamic extract and prostaglandin E1. Proc Natl Acad Sci USA. 1969;63:918–25.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Bourne HR, Lehrer RI, Cline MJ, Melmon KL. Cyclic 3′,5′-adenosine monophosphate in the human lukocyte: synthesis, degradation, andeffects n neutrophil candidacidal activity. J Clin Investig. 1971;50:920–9.CrossRefPubMedPubMedCentral Bourne HR, Lehrer RI, Cline MJ, Melmon KL. Cyclic 3′,5′-adenosine monophosphate in the human lukocyte: synthesis, degradation, andeffects n neutrophil candidacidal activity. J Clin Investig. 1971;50:920–9.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Bonta IL, Parnham MJ, Vanvliet L. Combination of theophylline and prostaglandin-E1 as inhibitors of adjuvant-induced arthritis syndrome of rats. Ann Rheum Dis. 1978;37:212–7.CrossRefPubMedPubMedCentral Bonta IL, Parnham MJ, Vanvliet L. Combination of theophylline and prostaglandin-E1 as inhibitors of adjuvant-induced arthritis syndrome of rats. Ann Rheum Dis. 1978;37:212–7.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Parnham MJ, Bonta IL, Adolfs MJP. Cyclic-Amp and prostaglandin-e in perfusates of rat hind paws during development of adjuvant arthritis. Ann Rheum Dis. 1978;37:218–24.CrossRefPubMedPubMedCentral Parnham MJ, Bonta IL, Adolfs MJP. Cyclic-Amp and prostaglandin-e in perfusates of rat hind paws during development of adjuvant arthritis. Ann Rheum Dis. 1978;37:218–24.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Meier R, Schuler W, Desaulles P. Zur Frage Des Mechanismus Der Hemmung Des Bindegewebswachstums Durch Cortisone. Experientia. 1950;6:469–71.CrossRefPubMed Meier R, Schuler W, Desaulles P. Zur Frage Des Mechanismus Der Hemmung Des Bindegewebswachstums Durch Cortisone. Experientia. 1950;6:469–71.CrossRefPubMed
16.
Zurück zum Zitat Mohr W, Hummler N, Pelster B, Wessinghage D. Proliferation of pannus tissue-cells in rheumatoid-arthritis. Rheumatol Int. 1986;6:127–32.CrossRefPubMed Mohr W, Hummler N, Pelster B, Wessinghage D. Proliferation of pannus tissue-cells in rheumatoid-arthritis. Rheumatol Int. 1986;6:127–32.CrossRefPubMed
17.
18.
Zurück zum Zitat Ohuchi K, Levine L, Sato H, Tsurufuji S. Prostaglandins E2, F2 alpha, 6-keto-F1 alpha and thromboxane B2 levels in carrageenin-induced inflammatory exudates in the rat air-pouch granuloma. Prostaglandins Med. 1979;2:293–7.CrossRefPubMed Ohuchi K, Levine L, Sato H, Tsurufuji S. Prostaglandins E2, F2 alpha, 6-keto-F1 alpha and thromboxane B2 levels in carrageenin-induced inflammatory exudates in the rat air-pouch granuloma. Prostaglandins Med. 1979;2:293–7.CrossRefPubMed
19.
Zurück zum Zitat Parnham MJ. The inflammatory response to lymph node cells from adjuvant-diseased rats: late changes in local and systemic leucocyte counts in the Wistar strain. J Pathol. 1980;132:11–21.CrossRefPubMed Parnham MJ. The inflammatory response to lymph node cells from adjuvant-diseased rats: late changes in local and systemic leucocyte counts in the Wistar strain. J Pathol. 1980;132:11–21.CrossRefPubMed
20.
Zurück zum Zitat Parnham MJ, Schoester GA. The inflammatory response to lymph node cells from adjuvant-diseased rats. Relative contributions of donor and recipient cell populations. J Pathol. 1980;130:255–63.CrossRefPubMed Parnham MJ, Schoester GA. The inflammatory response to lymph node cells from adjuvant-diseased rats. Relative contributions of donor and recipient cell populations. J Pathol. 1980;130:255–63.CrossRefPubMed
21.
Zurück zum Zitat Bonta IL, Adolfs MJP, Parnham MJ. Cannulated sponge implants in rats for the study of time-dependent pharmacological influences on inflammatory granulomata. J Pharmacol Method. 1979;2:1–11.CrossRef Bonta IL, Adolfs MJP, Parnham MJ. Cannulated sponge implants in rats for the study of time-dependent pharmacological influences on inflammatory granulomata. J Pharmacol Method. 1979;2:1–11.CrossRef
22.
Zurück zum Zitat Parnham MJ, Bonta IL, Adolfs MJ, Bragt P. A polyether sponge constituent which is antioxidant, anti-inflammatory and increases prostaglandin concentrations at the inflamed site. Agents Actions. 1977;7:539–44.CrossRefPubMed Parnham MJ, Bonta IL, Adolfs MJ, Bragt P. A polyether sponge constituent which is antioxidant, anti-inflammatory and increases prostaglandin concentrations at the inflamed site. Agents Actions. 1977;7:539–44.CrossRefPubMed
23.
Zurück zum Zitat Hansen AE, Burr GO. Essential fatty acids and human nutrition. J Am Med Assoc. 1946;132:855–9.CrossRefPubMed Hansen AE, Burr GO. Essential fatty acids and human nutrition. J Am Med Assoc. 1946;132:855–9.CrossRefPubMed
24.
25.
Zurück zum Zitat Bergstrom S, Carlson LA, Weeks JR. The prostaglandins: a family of biologically active lipids. Pharmacol Rev. 1968;20:1–48.PubMed Bergstrom S, Carlson LA, Weeks JR. The prostaglandins: a family of biologically active lipids. Pharmacol Rev. 1968;20:1–48.PubMed
26.
Zurück zum Zitat Bonta IL, Chrispijn H, Noordhoek J, Vincent JE. Reduction of prostaglandin-phase in hind-paw inflammation and partial failure of indomethacin to exert anti-inflammatory effect in rats on essential fatty acid deficient diet. Prostaglandins. 1974;5:495–503.CrossRefPubMed Bonta IL, Chrispijn H, Noordhoek J, Vincent JE. Reduction of prostaglandin-phase in hind-paw inflammation and partial failure of indomethacin to exert anti-inflammatory effect in rats on essential fatty acid deficient diet. Prostaglandins. 1974;5:495–503.CrossRefPubMed
27.
Zurück zum Zitat Vincent JE, Melai A, Bonta IL. Comparison of the effects of prostaglandin E1 on platelet aggregation in normal and essential fatty acid deficient rats. Prostaglandins. 1974;5:369–73.CrossRefPubMed Vincent JE, Melai A, Bonta IL. Comparison of the effects of prostaglandin E1 on platelet aggregation in normal and essential fatty acid deficient rats. Prostaglandins. 1974;5:369–73.CrossRefPubMed
28.
Zurück zum Zitat Bonta IL. Essential fatty acid deficient animals as tools for the study of some cardiovascular and related functions. Acta Cardiol Suppl. 1979:62–6. Bonta IL. Essential fatty acid deficient animals as tools for the study of some cardiovascular and related functions. Acta Cardiol Suppl. 1979:62–6.
29.
Zurück zum Zitat Parnham MJ, Vincent JE, Zijlstra FJ, Bonta IL. The use of essential fatty acid deficient rats to study pathophysiological roles of prostaglandins. Comparison of prostaglandin production with some parameters of deficiency. Lipids. 1979;14:407–12.CrossRefPubMed Parnham MJ, Vincent JE, Zijlstra FJ, Bonta IL. The use of essential fatty acid deficient rats to study pathophysiological roles of prostaglandins. Comparison of prostaglandin production with some parameters of deficiency. Lipids. 1979;14:407–12.CrossRefPubMed
30.
Zurück zum Zitat Bonta IL, Parnham MJ, Adolfs MJ. Reduced exudation and increased tissue proliferation during chronic inflammation in rats deprived of endogenous prostaglandin precursors. Prostaglandins. 1977;14:295–307.CrossRefPubMed Bonta IL, Parnham MJ, Adolfs MJ. Reduced exudation and increased tissue proliferation during chronic inflammation in rats deprived of endogenous prostaglandin precursors. Prostaglandins. 1977;14:295–307.CrossRefPubMed
31.
Zurück zum Zitat Parnham MJ, Shoshan S, Bonta IL, Neiman-Wollner S. Increased collagen metabolism in granulomata induced in rats deficient in endogenous prostaglandin precursors. Prostaglandins. 1977;14:709–14.CrossRefPubMed Parnham MJ, Shoshan S, Bonta IL, Neiman-Wollner S. Increased collagen metabolism in granulomata induced in rats deficient in endogenous prostaglandin precursors. Prostaglandins. 1977;14:709–14.CrossRefPubMed
32.
Zurück zum Zitat Bonta IL, Parnham MJ. Time-dependent stimulatory and inhibitory effects of prostaglandin E1 on exudative and tissue components of granulomatous inflammation in rats. Br J Pharmacol. 1979;65:465–72.CrossRefPubMedPubMedCentral Bonta IL, Parnham MJ. Time-dependent stimulatory and inhibitory effects of prostaglandin E1 on exudative and tissue components of granulomatous inflammation in rats. Br J Pharmacol. 1979;65:465–72.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Bonta IL, Parnham MJ. Essential fatty-acids or prostaglandins—therapeutic modulators of chronic inflammation. Trends Pharmacol Sci. 1980;1:347–9.CrossRef Bonta IL, Parnham MJ. Essential fatty-acids or prostaglandins—therapeutic modulators of chronic inflammation. Trends Pharmacol Sci. 1980;1:347–9.CrossRef
34.
Zurück zum Zitat Zhang YY, Desai A, Yang SY, Bae KB, Antczak MI, Fink SP, et al. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science. 2015;348:1223. Zhang YY, Desai A, Yang SY, Bae KB, Antczak MI, Fink SP, et al. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science. 2015;348:1223.
35.
Zurück zum Zitat Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin Immunol. 2015;27:200–15.CrossRefPubMedPubMedCentral Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin Immunol. 2015;27:200–15.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Newson J, Stables M, Karra E, Arce-Vargas F, Quezada S, Motwani M, et al. Resolution of acute inflammation bridges the gap between innate and adaptive immunity. Blood. 2014;124:1748–64.CrossRefPubMedPubMedCentral Newson J, Stables M, Karra E, Arce-Vargas F, Quezada S, Motwani M, et al. Resolution of acute inflammation bridges the gap between innate and adaptive immunity. Blood. 2014;124:1748–64.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Jacob RA. Three eras of vitamin C discovery. Sub Cell Biochem. 1996;25:1–16.CrossRef Jacob RA. Three eras of vitamin C discovery. Sub Cell Biochem. 1996;25:1–16.CrossRef
38.
Zurück zum Zitat Zhao ZJ, Li Q, Yang PZ, Wang H, Kong LC, Wang LH, et al. Selenium: a protective factor for Kaschin-Beck disease in Qing-Tibet Plateau. Biol Trace Elem Res. 2013;153:1–4.CrossRefPubMed Zhao ZJ, Li Q, Yang PZ, Wang H, Kong LC, Wang LH, et al. Selenium: a protective factor for Kaschin-Beck disease in Qing-Tibet Plateau. Biol Trace Elem Res. 2013;153:1–4.CrossRefPubMed
39.
Zurück zum Zitat Flohe L, Gunzler WA, Schock HH. Glutathione peroxidase: a selenoenzyme. FEBS Lett. 1973;32:132–4.CrossRefPubMed Flohe L, Gunzler WA, Schock HH. Glutathione peroxidase: a selenoenzyme. FEBS Lett. 1973;32:132–4.CrossRefPubMed
40.
Zurück zum Zitat Cadenas E, Wefers H, Muller A, Brigelius R, Sies H. Active oxygen metabolites and their action in the hepatocyte. Studies on chemiluminescence responses and alkane production. Agents Actions Suppl. 1982;11:203–16.PubMed Cadenas E, Wefers H, Muller A, Brigelius R, Sies H. Active oxygen metabolites and their action in the hepatocyte. Studies on chemiluminescence responses and alkane production. Agents Actions Suppl. 1982;11:203–16.PubMed
41.
Zurück zum Zitat Parnham MJ, Winkelmann J, Leyck S. Macrophage, lymphocyte and chronic inflammatory responses in selenium deficient rodents. Association with decreased glutathione peroxidase activity. Int J Immunopharmacol. 1983;5:455–61.CrossRefPubMed Parnham MJ, Winkelmann J, Leyck S. Macrophage, lymphocyte and chronic inflammatory responses in selenium deficient rodents. Association with decreased glutathione peroxidase activity. Int J Immunopharmacol. 1983;5:455–61.CrossRefPubMed
42.
Zurück zum Zitat Parnham MJ, Kindt S. A novel biologically active seleno-organic compound—III. Effects of PZ 51 (Ebselen) on glutathione peroxidase and secretory activities of mouse macrophages. Biochem Pharmacol. 1984;33:3247–50.CrossRefPubMed Parnham MJ, Kindt S. A novel biologically active seleno-organic compound—III. Effects of PZ 51 (Ebselen) on glutathione peroxidase and secretory activities of mouse macrophages. Biochem Pharmacol. 1984;33:3247–50.CrossRefPubMed
43.
Zurück zum Zitat Muller A, Cadenas E, Graf P, Sies H. A novel biologically active seleno-organic compound—I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen). Biochem Pharmacol. 1984;33:3235–9.CrossRefPubMed Muller A, Cadenas E, Graf P, Sies H. A novel biologically active seleno-organic compound—I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen). Biochem Pharmacol. 1984;33:3235–9.CrossRefPubMed
44.
Zurück zum Zitat Wendel A, Fausel M, Safayhi H, Tiegs G, Otter R. A novel biologically active seleno-organic compound—II. Activity of PZ 51 in relation to glutathione peroxidase. Biochem Pharmacol. 1984;33:3241–5.CrossRefPubMed Wendel A, Fausel M, Safayhi H, Tiegs G, Otter R. A novel biologically active seleno-organic compound—II. Activity of PZ 51 in relation to glutathione peroxidase. Biochem Pharmacol. 1984;33:3241–5.CrossRefPubMed
45.
Zurück zum Zitat Parnham MJ. Biological activities and clinical potential of Ebselen. Adv Exp Med Biol. 1990;264:193–7.CrossRefPubMed Parnham MJ. Biological activities and clinical potential of Ebselen. Adv Exp Med Biol. 1990;264:193–7.CrossRefPubMed
46.
Zurück zum Zitat Parnham MJ, Leyck S, Graf E, Dowling EJ, Blake DR. The pharmacology of ebselen. Agents Actions. 1991;32:4–9.CrossRefPubMed Parnham MJ, Leyck S, Graf E, Dowling EJ, Blake DR. The pharmacology of ebselen. Agents Actions. 1991;32:4–9.CrossRefPubMed
47.
Zurück zum Zitat Leyck S, Parnham MJ. Acute antiinflammatory and gastric effects of the seleno-organic compound ebselen. Agents Actions. 1990;30:426–31.CrossRefPubMed Leyck S, Parnham MJ. Acute antiinflammatory and gastric effects of the seleno-organic compound ebselen. Agents Actions. 1990;30:426–31.CrossRefPubMed
48.
Zurück zum Zitat Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature. 1980;283:666–8.CrossRefPubMed Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature. 1980;283:666–8.CrossRefPubMed
49.
Zurück zum Zitat Koga T, Kakimoto K, Hirofuji T, Kotani S, Ohkuni H, Watanabe K, et al. Acute joint inflammation in mice after systemic injection of the cell wall, its peptidoglycan, and chemically defined peptidoglycan subunits from various bacteria. Infect Immun. 1985;50:27–34.PubMedPubMedCentral Koga T, Kakimoto K, Hirofuji T, Kotani S, Ohkuni H, Watanabe K, et al. Acute joint inflammation in mice after systemic injection of the cell wall, its peptidoglycan, and chemically defined peptidoglycan subunits from various bacteria. Infect Immun. 1985;50:27–34.PubMedPubMedCentral
50.
Zurück zum Zitat van den Broek MF, van Bruggen MC, van de Putte LB, van den Berg WB. T cell responses to streptococcal antigens in rats: relation to susceptibility to streptococcal cell wall-induced arthritis. Cell Immunol. 1988;116:216–29.CrossRefPubMed van den Broek MF, van Bruggen MC, van de Putte LB, van den Berg WB. T cell responses to streptococcal antigens in rats: relation to susceptibility to streptococcal cell wall-induced arthritis. Cell Immunol. 1988;116:216–29.CrossRefPubMed
51.
Zurück zum Zitat van den Broek MF, van den Berg WB, van de Putte LB, Severijnen AJ. Streptococcal cell wall-induced arthritis and flare-up reaction in mice induced by homologous or heterologous cell walls. Am J Pathol. 1988;133:139–49.PubMedPubMedCentral van den Broek MF, van den Berg WB, van de Putte LB, Severijnen AJ. Streptococcal cell wall-induced arthritis and flare-up reaction in mice induced by homologous or heterologous cell walls. Am J Pathol. 1988;133:139–49.PubMedPubMedCentral
52.
Zurück zum Zitat van den Broek MF, van den Berg WB, Arntz OJ, van de Putte LB. Reaction of bacterium-primed murine T cells to cartilage components: a clue for the pathogenesis of arthritis? Clin Exp Immunol. 1988;72:9–14.PubMedPubMedCentral van den Broek MF, van den Berg WB, Arntz OJ, van de Putte LB. Reaction of bacterium-primed murine T cells to cartilage components: a clue for the pathogenesis of arthritis? Clin Exp Immunol. 1988;72:9–14.PubMedPubMedCentral
53.
Zurück zum Zitat Schalkwijk J, van den Berg WB, van de Putte LB, Joosten LA. An experimental model for hydrogen peroxide-induced tissue damage. Effects of a single inflammatory mediator on (peri)articular tissues. Arthritis Rheum. 1986;29:532–8.CrossRefPubMed Schalkwijk J, van den Berg WB, van de Putte LB, Joosten LA. An experimental model for hydrogen peroxide-induced tissue damage. Effects of a single inflammatory mediator on (peri)articular tissues. Arthritis Rheum. 1986;29:532–8.CrossRefPubMed
54.
Zurück zum Zitat Parnham MJ, Sies H. The early research and development of ebselen. Biochem Pharmacol. 2013;86:1248–53.CrossRefPubMed Parnham MJ, Sies H. The early research and development of ebselen. Biochem Pharmacol. 2013;86:1248–53.CrossRefPubMed
56.
Zurück zum Zitat Novac N. Challenges and opportunities of drug repositioning. Trends Pharmacol Sci. 2013;34:267–72.CrossRefPubMed Novac N. Challenges and opportunities of drug repositioning. Trends Pharmacol Sci. 2013;34:267–72.CrossRefPubMed
57.
58.
Zurück zum Zitat Mason RP, Casu M, Butler N, Breda C, Campesan S, Clapp J, et al. Glutathione peroxidase activity is neuroprotective in models of Huntington’s disease. Nat Genet. 2013;45:1249–54.CrossRefPubMedPubMedCentral Mason RP, Casu M, Butler N, Breda C, Campesan S, Clapp J, et al. Glutathione peroxidase activity is neuroprotective in models of Huntington’s disease. Nat Genet. 2013;45:1249–54.CrossRefPubMedPubMedCentral
59.
Zurück zum Zitat Carbon C. Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. Clin Infect Dis. 1998;27:28–32.CrossRefPubMed Carbon C. Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. Clin Infect Dis. 1998;27:28–32.CrossRefPubMed
60.
Zurück zum Zitat Alihodzic S, Fajdetic A, Kobrehel G, Lazarevski G, Mutak S, Pavlovic D, et al. Synthesis and antibacterial activity of isomeric 15-membered azalides. J Antibiot. 2006;59:753–69.CrossRefPubMed Alihodzic S, Fajdetic A, Kobrehel G, Lazarevski G, Mutak S, Pavlovic D, et al. Synthesis and antibacterial activity of isomeric 15-membered azalides. J Antibiot. 2006;59:753–69.CrossRefPubMed
61.
Zurück zum Zitat Fajdetic A, Vinter A, Paljetak HC, Padovan J, Jakopovic IP, Kapic S, et al. Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. Eur J Med Chem. 2011;46:3388–97.CrossRefPubMed Fajdetic A, Vinter A, Paljetak HC, Padovan J, Jakopovic IP, Kapic S, et al. Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. Eur J Med Chem. 2011;46:3388–97.CrossRefPubMed
62.
Zurück zum Zitat Tomaskovic L, Komac M, Makaruha Stegic O, Munic V, Ralic J, Stanic B, et al. Macrolactonolides: a novel class of anti-inflammatory compounds. Bioorg Med Chem. 2013;21:321–32.CrossRefPubMed Tomaskovic L, Komac M, Makaruha Stegic O, Munic V, Ralic J, Stanic B, et al. Macrolactonolides: a novel class of anti-inflammatory compounds. Bioorg Med Chem. 2013;21:321–32.CrossRefPubMed
63.
Zurück zum Zitat Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol. 2001;429:209–29.CrossRefPubMed Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol. 2001;429:209–29.CrossRefPubMed
64.
Zurück zum Zitat Culic O, Erakovic V, Cepelak I, Barisic K, Brajsa K, Ferencic Z, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;450:277–89.CrossRefPubMed Culic O, Erakovic V, Cepelak I, Barisic K, Brajsa K, Ferencic Z, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;450:277–89.CrossRefPubMed
65.
Zurück zum Zitat Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Therap. 2014;143:225–45.CrossRef Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Therap. 2014;143:225–45.CrossRef
66.
Zurück zum Zitat Parnham MJ, Culic O, Erakovic V, Munic V, Popovic-Grle S, Barisic K, et al. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol. 2005;517:132–43.CrossRefPubMed Parnham MJ, Culic O, Erakovic V, Munic V, Popovic-Grle S, Barisic K, et al. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol. 2005;517:132–43.CrossRefPubMed
67.
Zurück zum Zitat Ivetic Tkalcevic V, Bosnjak B, Hrvacic B, Bosnar M, Marjanovic N, Ferencic Z, et al. Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Eur J Pharmacol. 2006;539:131–8.CrossRefPubMed Ivetic Tkalcevic V, Bosnjak B, Hrvacic B, Bosnar M, Marjanovic N, Ferencic Z, et al. Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Eur J Pharmacol. 2006;539:131–8.CrossRefPubMed
68.
Zurück zum Zitat Bosnar M, Bosnjak B, Cuzic S, Hrvacic B, Marjanovic N, Glojnaric I, et al. Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1beta. J Pharmacol Exp Therap. 2009;331:104–13.CrossRef Bosnar M, Bosnjak B, Cuzic S, Hrvacic B, Marjanovic N, Glojnaric I, et al. Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1beta. J Pharmacol Exp Therap. 2009;331:104–13.CrossRef
69.
Zurück zum Zitat Hodge S, Hodge G, Brozyna S, Jersmann H, Holmes M, Reynolds PN. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J. 2006;28:486–95.CrossRefPubMed Hodge S, Hodge G, Brozyna S, Jersmann H, Holmes M, Reynolds PN. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J. 2006;28:486–95.CrossRefPubMed
70.
Zurück zum Zitat Feola DJ, Garvy BA, Cory TJ, Birket SE, Hoy H, Hayes D Jr, et al. Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. Antimicrob Agents Chemother. 2010;54:2437–47.CrossRefPubMedPubMedCentral Feola DJ, Garvy BA, Cory TJ, Birket SE, Hoy H, Hayes D Jr, et al. Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. Antimicrob Agents Chemother. 2010;54:2437–47.CrossRefPubMedPubMedCentral
71.
Zurück zum Zitat Bosnar M, Cuzic S, Bosnjak B, Nujic K, Ergovic G, Marjanovic N, et al. Azithromycin inhibits macrophage interleukin-1beta production through inhibition of activator protein-1 in lipopolysaccharide-induced murine pulmonary neutrophilia. Int Immunopharmacol. 2011;11:424–34.CrossRefPubMed Bosnar M, Cuzic S, Bosnjak B, Nujic K, Ergovic G, Marjanovic N, et al. Azithromycin inhibits macrophage interleukin-1beta production through inhibition of activator protein-1 in lipopolysaccharide-induced murine pulmonary neutrophilia. Int Immunopharmacol. 2011;11:424–34.CrossRefPubMed
72.
Zurück zum Zitat Gualdoni GA, Lingscheid T, Schmetterer KG, Hennig A, Steinberger P, Zlabinger GJ. Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation. Sci Rep. 2015;5:12016.CrossRefPubMedPubMedCentral Gualdoni GA, Lingscheid T, Schmetterer KG, Hennig A, Steinberger P, Zlabinger GJ. Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation. Sci Rep. 2015;5:12016.CrossRefPubMedPubMedCentral
73.
Zurück zum Zitat Vos R, Vanaudenaerde BM, Ottevaere A, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transplant. 2010;29:1358–68.CrossRefPubMed Vos R, Vanaudenaerde BM, Ottevaere A, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transplant. 2010;29:1358–68.CrossRefPubMed
74.
Zurück zum Zitat Vos R, Verleden SE, Ruttens D, Vandermeulen E, Bellon H, Neyrinck A, et al. Azithromycin and the treatment of lymphocytic airway inflammation after lung transplantation. Am J Transplant. 2014;14:2736–48.CrossRefPubMed Vos R, Verleden SE, Ruttens D, Vandermeulen E, Bellon H, Neyrinck A, et al. Azithromycin and the treatment of lymphocytic airway inflammation after lung transplantation. Am J Transplant. 2014;14:2736–48.CrossRefPubMed
75.
Zurück zum Zitat Ruttens D, Verleden SE, Vandermeulen E, Bellon H, Vanaudenaerde BM, Somers J, et al. Prophylactic azithromycin therapy after lung transplantation: post hoc analysis of a randomized controlled trial. Am J Transpl; 2016;16:254–61.CrossRef Ruttens D, Verleden SE, Vandermeulen E, Bellon H, Vanaudenaerde BM, Somers J, et al. Prophylactic azithromycin therapy after lung transplantation: post hoc analysis of a randomized controlled trial. Am J Transpl; 2016;16:254–61.CrossRef
76.
Zurück zum Zitat Navarro-Xavier RA, Newson J, Silveira VLF, Farrow SN, Gilroy DW, Bystrom J. A New strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J Immunol. 2010;184:1516–25.CrossRefPubMed Navarro-Xavier RA, Newson J, Silveira VLF, Farrow SN, Gilroy DW, Bystrom J. A New strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J Immunol. 2010;184:1516–25.CrossRefPubMed
77.
Zurück zum Zitat Vrancic M, Banjanac M, Nujic K, Bosnar M, Murati T, Munic V, et al. Azithromycin distinctively modulates classical activation of human monocytes in vitro. Br J Pharmacol. 2012;165:1348–60.CrossRefPubMedPubMedCentral Vrancic M, Banjanac M, Nujic K, Bosnar M, Murati T, Munic V, et al. Azithromycin distinctively modulates classical activation of human monocytes in vitro. Br J Pharmacol. 2012;165:1348–60.CrossRefPubMedPubMedCentral
78.
Zurück zum Zitat Polancec DS, Kos VM, Banjanac M, Vrancic M, Cuzic S, Belamaric D, et al. Azithromycin drives in vitro GM-CSF/IL-4-induced differentiation of human blood monocytes toward dendritic-like cells with regulatory properties. J Leukocyte Biol. 2012;91:229–43.CrossRefPubMed Polancec DS, Kos VM, Banjanac M, Vrancic M, Cuzic S, Belamaric D, et al. Azithromycin drives in vitro GM-CSF/IL-4-induced differentiation of human blood monocytes toward dendritic-like cells with regulatory properties. J Leukocyte Biol. 2012;91:229–43.CrossRefPubMed
79.
Zurück zum Zitat Erakovic Haber V, Bosnar M, Kragol G. The design of novel classes of macrolides for neutrophil-dominated inflammatory diseases. Future Med Chem. 2014;6:657–74.CrossRefPubMed Erakovic Haber V, Bosnar M, Kragol G. The design of novel classes of macrolides for neutrophil-dominated inflammatory diseases. Future Med Chem. 2014;6:657–74.CrossRefPubMed
80.
Zurück zum Zitat Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11:191–200.CrossRefPubMed Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11:191–200.CrossRefPubMed
81.
Zurück zum Zitat Bleicher KH, Bohm HJ, Muller K, Alanine AI. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov. 2003;2:369–78.CrossRefPubMed Bleicher KH, Bohm HJ, Muller K, Alanine AI. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov. 2003;2:369–78.CrossRefPubMed
82.
Zurück zum Zitat Schirle M, Jenkins JL. Identifying compound efficacy targets in phenotypic drug discovery. Drug Discov Today. 2016;21:82–9.CrossRefPubMed Schirle M, Jenkins JL. Identifying compound efficacy targets in phenotypic drug discovery. Drug Discov Today. 2016;21:82–9.CrossRefPubMed
83.
Zurück zum Zitat Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44:235–49.CrossRefPubMed Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44:235–49.CrossRefPubMed
84.
Zurück zum Zitat Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1:337–41.CrossRefPubMed Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1:337–41.CrossRefPubMed
85.
Zurück zum Zitat Vincent F, Loria P, Pregel M, Stanton R, Kitching L, Nocka K, et al. Developing predictive assays: the phenotypic screening “rule of 3”. Sci Transl Med. 2015;7:293ps15.CrossRefPubMed Vincent F, Loria P, Pregel M, Stanton R, Kitching L, Nocka K, et al. Developing predictive assays: the phenotypic screening “rule of 3”. Sci Transl Med. 2015;7:293ps15.CrossRefPubMed
86.
Zurück zum Zitat Dorward DA, Lucas CD, Rossi AG, Haslett C, Dhaliwal K. Imaging inflammation: molecular strategies to visualize key components of the inflammatory cascade, from initiation to resolution. Pharmacol Ther. 2012;135:182–99.CrossRefPubMed Dorward DA, Lucas CD, Rossi AG, Haslett C, Dhaliwal K. Imaging inflammation: molecular strategies to visualize key components of the inflammatory cascade, from initiation to resolution. Pharmacol Ther. 2012;135:182–99.CrossRefPubMed
87.
Zurück zum Zitat Cunha L, Horvath I, Ferreira S, Lemos J, Costa P, Vieira D, et al. Preclinical imaging: an essential ally in modern biosciences. Mol Diagn Therapy. 2014;18:153–73.CrossRef Cunha L, Horvath I, Ferreira S, Lemos J, Costa P, Vieira D, et al. Preclinical imaging: an essential ally in modern biosciences. Mol Diagn Therapy. 2014;18:153–73.CrossRef
88.
Zurück zum Zitat Busch W, Duis K, Fenske M, Maack G, Legler J, Padilla S, et al. The zebrafish embryo model in toxicology and teratology, September 2–3, 2010, Karlsruhe, Germany. Reprod Toxicol. 2011;31:585–8.CrossRefPubMed Busch W, Duis K, Fenske M, Maack G, Legler J, Padilla S, et al. The zebrafish embryo model in toxicology and teratology, September 2–3, 2010, Karlsruhe, Germany. Reprod Toxicol. 2011;31:585–8.CrossRefPubMed
89.
Zurück zum Zitat Bruni G, Lakhani P, Kokel D. Discovering novel neuroactive drugs through high-throughput behavior-based chemical screening in the zebrafish. Front Pharmacol. 2014;5:153.CrossRefPubMedPubMedCentral Bruni G, Lakhani P, Kokel D. Discovering novel neuroactive drugs through high-throughput behavior-based chemical screening in the zebrafish. Front Pharmacol. 2014;5:153.CrossRefPubMedPubMedCentral
90.
Zurück zum Zitat Schmitz K, de Bruin N, Bishay P, Mannich J, Haussler A, Altmann C, et al. R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice. EMBO Mol Med. 2014;6:1398–422.CrossRefPubMedPubMedCentral Schmitz K, de Bruin N, Bishay P, Mannich J, Haussler A, Altmann C, et al. R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice. EMBO Mol Med. 2014;6:1398–422.CrossRefPubMedPubMedCentral
91.
Zurück zum Zitat De Bruin NMWJ, Schmitz K, Tegeder I, Talmon S, Jordan H, Schmidt M, et al. Treatment with FTY-720 reverses social recognition deficits without affecting clinical scores or impaired motor performance in EAE in SJL mice. J Neuroimmunol. 2014;275:115.CrossRef De Bruin NMWJ, Schmitz K, Tegeder I, Talmon S, Jordan H, Schmidt M, et al. Treatment with FTY-720 reverses social recognition deficits without affecting clinical scores or impaired motor performance in EAE in SJL mice. J Neuroimmunol. 2014;275:115.CrossRef
92.
Zurück zum Zitat Finn CA. Artifacts: An Archaeologist's Year in Silicon Valley 2001. MIT Press, Cambridge, MA, p. 90 Finn CA. Artifacts: An Archaeologist's Year in Silicon Valley 2001. MIT Press, Cambridge, MA, p. 90
Metadaten
Titel
Progress does not just come in giant leaps: adapting techniques for the study of inflammation to novel applications
verfasst von
Michael J. Parnham
Publikationsdatum
28.09.2016
Verlag
Springer International Publishing
Erschienen in
Inflammation Research / Ausgabe 1/2017
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-016-0988-0

Weitere Artikel der Ausgabe 1/2017

Inflammation Research 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.